Propel Bio Management, LLC

LOS ANGELES, CA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 13, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$188.6M2026 Q3
Positions30
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.68.3%

Propel Bio Management, LLC reported 30 positions worth $188.6M as of September 30, 2026 (13F filed November 13, 2026). Largest holding: PAGP (17.5%). Biggest move: reduce AQST ($35.9M).

10 / 30 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 PAGPPlains GP$33.0M17.47%1,272,360——+1.8%
▸ 2 ACHVAchieve Life Sciences$31.3M16.57%3,864,148——-21.9%
▸ 3 DCTHDelcath Systems$9.7M5.12%604,664——+24.4%
▸ 4 COLLCollegium Pharmaceutical$9.0M4.75%410,175———
▸ 5 CORTCorcept Therapeutics$8.7M4.60%75,274——-39.9%
▸ 6 AQSTAquestive Therapeutics$8.6M4.56%278,723——-18.8%
▸ 7 MISTMilestone Pharmaceuticals$8.2M4.34%9,449,727———
▸ 8 PHATPhathom Pharmaceuticals$8.1M4.28%1,105,913——-17.0%
▸ 9 CMPSCOMPASS Pathways$6.8M3.62%549,186——-33.5%
▸ 10 OBIOOrchestra BioMed$5.6M2.96%896,701——+14.5%

Pro Feature

The remaining 20 positions with Pro.

Upgrade to Pro

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does Propel Bio Management, LLC hold as of Q3 2026?

Propel Bio Management, LLC reported 30 positions worth $188.6M in its Q3 2026 13F filing. Largest positions: PAGP (17.5%), ACHV (16.6%), DCTH (5.1%), COLL (4.7%) and CORT (4.6%).

What did Propel Bio Management, LLC buy in Q3 2026?

New positions: COLL, CABA, PROK, IRD and SGP. Added to: MAZE, CRVS, MIST, PHAT and SABS.

What did Propel Bio Management, LLC sell in Q3 2026?

Reduced: AQST, CORT, DCTH, CLDX and ACHV (15 in all). Sold out entirely: ZVRA, EYPT, SLN and SGMT.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.